• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nutex Health Inc.

    11/14/24 11:02:17 AM ET
    $NUTX
    Business Services
    Consumer Discretionary
    Get the next $NUTX alert in real time by email
    SC 13G 1 p24-3244sc13g.htm NUTEX HEALTH, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    Nutex Health Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    67079U306

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 67079U30613GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    294,592 shares of Common Stock issuable upon the exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    294,592 shares of Common Stock issuable upon the exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    294,592 shares of Common Stock issuable upon the exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    [5.5]%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 67079U30613GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Nutex Health Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at ‎6030 S. Rice Ave, Suite C, Houston, Texas 77081.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Highbridge Capital Management, LLC (“Highbridge” or the “Reporting Person”), a Delaware limited liability company and the investment adviser to certain funds and accounts (the “Highbridge Funds”), with respect to the shares of Common Stock (as defined in Item 2(d) below) underlying warrants directly held by the Highbridge Funds.
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:
       
      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      67079U306

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,

     

    CUSIP No. 67079U30613GPage 4 of 6 Pages

     

      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E),
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ________________________________________________________

     

    Item 4. OWNERSHIP:
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 5,065,709 shares of Common Stock reported to be outstanding as of August 5, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024, and assumes the exercise of the warrants held by the Highbridge Funds.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    CUSIP No. 67079U30613GPage 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 67079U30613GPage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
       
       
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  

     

    Get the next $NUTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUTX

    DatePrice TargetRatingAnalyst
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    9/18/2024$45.00Buy
    Maxim Group
    2/22/2023$3.00Outperform
    Northland Capital
    More analyst ratings

    $NUTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      11/14/24 11:02:17 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Nutex Health Inc. (Amendment)

      SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)

      9/26/23 4:26:07 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by Nutex Health Inc.

      SC 13G - Nutex Health, Inc. (0001479681) (Subject)

      7/7/23 5:03:39 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Leadership Updates

    Live Leadership Updates

    See more
    • NUTEX HEALTH ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

      HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors.  They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s

      4/22/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER

      HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c

      9/5/23 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JON BATES AS ITS NEW CHIEF FINANCIAL OFFICER

      HOUSTON, June 10, 2022 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, today announced the appointment of Jon Bates as the Company's Chief Financial Officer effective on or about June 30, 2022. On May 3, 2022, Michael Bowen notified the company that he intends to retire as Chief Financial Officer of the Company. In connection with Mr. Bowen's retirement, the Company's Board formed a search committee.  On June 8, 2022, the Company announced the appointme

      6/10/22 6:00:00 AM ET
      $NUTX
      $USPH
      Business Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $NUTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0%ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTSHOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NA

      5/13/25 5:43:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      FULL YEAR 2024 HIGHLIGHTS: TOTAL REVENUE OF $479.9 MILLION VERSUS $247.6 MILLION IN 2023, AN INCREASE OF 93.8%NET INCOME OF $52.2 MILLION VERSUS NET LOSS OF $45.8 MILLION IN 2023DILUTED EPS OF $9.71 PER SHARE VERSUS $(10.39) PER SHARE IN 2023EBITDA OF $98.4 MILLION VERSUS $(22.5) MILLION IN EBITDA IN 2023ADJUSTED EBITDA OF $123.7 MILLION VERSUS $10.8 MILLION IN 2023, AN INCREASE OF 1,045.4%NET CASH FROM OPERATING ACTIVITIES OF $23.2 MILLIONCOMPANY BELIEVES ITS ARBITRATION EFFORTS, THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS, HAS RESULTED IN MORE EQUITABLE PAYMENTSHOUSTON, March 31, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physicia

      3/31/25 4:30:00 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    SEC Filings

    See more
    • Nutex Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:31:29 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Nutex Health Inc.

      10-Q - Nutex Health, Inc. (0001479681) (Filer)

      5/13/25 4:28:53 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • SEC Form 424B3 filed by Nutex Health Inc.

      424B3 - Nutex Health, Inc. (0001479681) (Filer)

      5/2/25 4:35:17 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Director Spears Kelvin converted options into 143 shares and covered exercise/tax liability with 34 shares, increasing direct ownership by 0.34% to 31,992 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:15:36 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua converted options into 2,125 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 35% to 6,481 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:01:59 PM ET
      $NUTX
      Business Services
      Consumer Discretionary

    $NUTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NUTX
    Financials

    Live finance-specific insights

    See more

    $NUTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chief Financial Officer Bates Jon Christian converted options into 1,611 shares and bought $81,810 worth of shares (1,000 units at $81.81), increasing direct ownership by 115% to 4,888 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      4/14/25 4:30:48 PM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Financial Officer Bates Jon Christian bought $28,970 worth of shares (1,350 units at $21.46), increasing direct ownership by 146% to 2,277 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      8/26/24 11:54:30 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Chief Operating Officer Detillio Joshua bought $10,800 worth of shares (20,000 units at $0.54), increasing direct ownership by 214% to 29,333 units (SEC Form 4)

      4 - Nutex Health, Inc. (0001479681) (Issuer)

      6/13/24 11:50:03 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

      HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=com

      5/7/25 6:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, March 17, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of the stock market on March 27th, 2025. The Company will discuss those results on a conference call on Friday, March 28st, 2025, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://viavid.webcasts.com/starthere.jsp?ei=1706653&tp_key=5e3e4c2f6

      3/17/25 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • NUTEX HEALTH SCHEDULES 2024 THIRD QUARTER FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

      HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce

      11/5/24 5:30:00 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Maxim Group reiterated coverage on Nutex Health with a new price target

      Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously

      11/12/24 8:15:57 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Maxim Group initiated coverage on Nutex Health with a new price target

      Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00

      9/18/24 8:12:45 AM ET
      $NUTX
      Business Services
      Consumer Discretionary
    • Northland Capital initiated coverage on Nutex Health with a new price target

      Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00

      2/22/23 9:08:40 AM ET
      $NUTX
      Business Services
      Consumer Discretionary